🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Global Health Concern

Gonorrhoea infections are increasing around the world, with data suggesting more than 82 million new cases annually. Notably increased rates are seen in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, the spread of superbugs and the extremely scarce available drugs at this time.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for medication research. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

Based on data detailed in a prominent scientific publication, zoliflodacin cured the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which combines two antibiotics. The study enrolled over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the authority to make available and distribute the drug in numerous developing nations.

Medical professionals on the front lines have voiced optimism. The availability of a single-dose, oral treatment like this is hailed as a "revolutionary step" for gonorrhoea control. This is considered crucial to reduce the burden of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.